Our results showed that the frequency of T-bet expressing and IFN-γ producing XBP1-CTL was consistently higher in total CD3+CD8+ T cells after lenalidamide treatment, as compared to untreated XBP1-CTL in response to breast cancer (MDA-MB231, Figure 6A), pancreatic cancer (Panc1, Figure 6B) or colon cancer (SW480, Figure 6C) cells. Here, XBP1 is linked to malignant colon neoplasm.